TP53 and ovarian carcinoma: While there are no previous reports about IP6K2 in relation to enzalutamide resistance specifically or PC in general, other studies have demonstrated a pro-apoptotic role of IP6K2 in ovarian carcinoma cells24 and colon cancer cells25, mediated by p53-binding26.